OAM
RDHL

Oxford Asset Management’s Redhill Biopharma RDHL Stock Holding History

Oxford Asset Management’s Portfolio RDHL Stock Details RDHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-25
Closed -$138K – 1923
2018
Q4 		$138K Buy
+25
New +$192K ﹤0.01% 1611

Other funds holding RDHL

6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Oxford Asset Management's RDHL Position: Q1 2019 in Review

Oxford Asset Management sold out of Redhill Biopharma (RDHL) in Q1 2019, closing a stake of 25 shares — an estimated $138K sold.

Oxford Asset Management first reported a position in RDHL in Q4 2018 and held it in 1 quarter. The position peaked at $138K in Q4 2018. 34 funds tracked by Wall St. Rank hold RDHL as of Q1 2019.

  • Oxford Asset Management reported no remaining Redhill Biopharma position as of Q1 2019 after selling out during the quarter.
  • Oxford Asset Management sold 25 Redhill Biopharma shares in Q1 2019, an estimated $138K.
  • Oxford Asset Management first reported a position in Redhill Biopharma in Q4 2018 and held it in 1 quarter.
  • Oxford Asset Management's Redhill Biopharma position peaked at $138K in Q4 2018.
  • 34 funds tracked by Wall St. Rank held Redhill Biopharma as of Q1 2019.

Based on Oxford Asset Management's 13F filing for Q1 2019, filed 15 May 2019.